ICICI Securities Limited
Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).
Alkem Laboratories L.. has an average target of 5562.33 from 3 brokers.
More from Alkem Laboratories Ltd.
Recommended